Design Therapeutics (DSGN) Liabilities and Shareholders Equity (2020 - 2026)

Design Therapeutics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $230.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $230.4 million, down 2.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $891.3 million (down 12.68% YoY), and the FY2025 annual result was $226.2 million, down 10.27% from the prior year.
• Liabilities and Shareholders Equity came in at $230.4 million for Q1 2026 at Design Therapeutics, up from $226.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $378.8 million in Q1 2022 to a low of $211.8 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $278.8 million (2024), against an average of $285.8 million.
• Across the five-year window, Liabilities and Shareholders Equity declined 19.06% in 2025 and dropped 2.96% in 2026, its largest moves.
• Design Therapeutics' Liabilities and Shareholders Equity stood at $341.1 million in 2022, then slipped by 15.09% to $289.6 million in 2023, then slipped by 12.96% to $252.1 million in 2024, then decreased by 10.27% to $226.2 million in 2025, then increased by 1.87% to $230.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $230.4 million (Q1 2026), $226.2 million (Q4 2025), and $211.8 million (Q3 2025), per Business Quant data.